Collegium Pharmaceutical (COLL) has completed a roughly US$655.6 million cash acquisition of ADHD drug Azstarys from Corium Therapeutics, adding a new central nervous system stimulant to its portfolio and updating financial guidance for 2026.

At a share price of US$37.03, Collegium Pharmaceutical has seen a 19.22% 1 month share price return and a 14.61% 3 month share price return. Its 1 year total shareholder return of 22.01% and 3 year total shareholder return of 70.33% point to momentum that investors are weighing against its updated 2026 guidance and expanding ADHD portfolio.

If this kind of specialty pharma story interests you, it can be useful to compare it with other healthcare companies applying AI to drug development and diagnostics using the 40 healthcare AI stocks

With Collegium Pharmaceutical trading at US$37.03 against an analyst price target of about US$54.33 and flagged as having an intrinsic discount, you have to ask: is there still value on the table, or is the market already pricing in future growth?

Most Popular Narrative: 31.8% Undervalued

With Collegium Pharmaceutical last closing at $37.03 versus a narrative fair value of $54.33, the most followed view is that the stock trades at a meaningful discount while its earnings profile evolves.

The company's differentiated pain portfolio, notably with products featuring proprietary abuse-deterrent and extended-release technologies (for example, Xtampza ER's DETERx platform), is supported by industry and regulatory trends that increasingly favor safer opioid options. This likely enhances market share, pricing power, and sustains net margins as regulatory emphasis on abuse deterrence grows. This underappreciated expansion directly supports revenue and total earnings growth.

Curious what sits behind that fair value for Collegium Pharmaceutical? The narrative leans on steady revenue expansion, a sharp earnings ramp, and a lower future earnings multiple than many investors might expect.

Result: Fair Value of $54.33 (UNDERVALUED)

However, Collegium Pharmaceutical still faces concentration in a maturing pain portfolio and exposure to tighter opioid regulation, either of which could quickly challenge this undervalued narrative.

Next Steps

Given the mix of enthusiasm and caution around Collegium Pharmaceutical, it makes sense to look at the numbers yourself and decide quickly where you stand. You can start with the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Collegium Pharmaceutical?

If you are serious about building a stronger portfolio alongside Collegium Pharmaceutical, do not stop at a single stock story. Widen your search with high quality screeners.

• Spot opportunities with quality and value on your side by reviewing companies in the 43 high quality undervalued stocks.
• Prioritize resilience and peace of mind by scanning for companies featured in the 75 resilient stocks with low risk scores.
• Hunt for underfollowed potential by checking the screener containing 18 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.